Bristol-Myers's Grand Ambitions in Oncology
Executive Summary
Bristol-Myers aims to become an oncology powerhouse in the next five years. Through M&A, alliances, and internal R&D, Bristol-Myers is building an armamentarium of oncology assets that allows it to take multiple "shots on goal." It is leveraging its past experiences in the field as it also adds new skill sets in biologics, market access, and biomarkers. But the market has become more competitive, as companies look to participate in one of the few growth areas of pharma. Bristol, like others, is carving out space in the Avastin-ineligible or -intolerant portion of the market, particularly in the gastrointestinal, colorectal, and head-and-neck cancer areas. Even if successful, current late-stage development projects aren't likely to contribute much to revenues before 2011-and oncology products have slow ramp-ups. With a patent cliff looming in 2012, the company needs new products now.
You may also be interested in...
Everyone Wins In Deal Between BMS And The Medicines Co.
Bristol-Myers Squibb has agreed to license its already-marketed topical hemostat to The Medicines Company for $115 million upfront and royalties. The agreement will last for two years and add to The Medicines Co.'s portfolio of perioperative care products.
Making The Case For Antibody-Drug Conjugates
After 30 years and one market failure, antibody-drug conjugate developers have produced two strong clinical candidates, with a lot more coming in the pipeline. Can two successes turn into the next great therapeutic platform?
Making The Case For Antibody-Drug Conjugates
After 30 years and one market failure, antibody-drug conjugate developers have produced two strong clinical candidates, with a lot more coming in the pipeline. Can two successes turn into the next great therapeutic platform?